Case Reports

Diffuse large B-cell lymphoma of the lung in a 63-year-old man with left flank pain


 

Diffuse large B-cell lymphoma of the lung is a rare entity, and although the prognosis is favorable, its biological features, clinical presentation, prognostic markers, and treatment have not been well defined.1,2 It is the second most common primary pulmonary lymphoma after mucosa-associated lymphoid tissue. PPL itself is very rare; it represents 3%-4% of extranodal non-Hodgkin lymphoma, less than 1% of NHL, and 0.5%-1.0% of primary pulmonary malignancies.2,3 A review of the literature indicates a lack of data on pulmonary DLBCL. The objective of this case report is to highlight areas in which further research may be pursued to better understand this disease.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Rapid response to chemotherapy in a patient with thymoma with pericardial effusion
MDedge Hematology and Oncology
Early myeloablative therapy may benefit subset of high-risk non-Hodgkin’s lymphoma patients
MDedge Hematology and Oncology
Low-intensity chemo works for Burkitt’s lymphoma
MDedge Hematology and Oncology
Electrocautery incision of lymph nodes improved biopsy yield
MDedge Hematology and Oncology
Treated T-cells induce remissions in chemo-refractory B-cell lymphomas
MDedge Hematology and Oncology
Continuous lenalidomide plus dexamethasone ups progression-free survival
MDedge Hematology and Oncology
VIDEO: Idelalisib shows promise in refractory non-Hodgkin lymphoma
MDedge Hematology and Oncology
Dawn of a new era: targeting the B-cell receptor signaling pathway to conquer B-cell lymphomas
MDedge Hematology and Oncology
NICE again rejects pixantrone for NHL
MDedge Hematology and Oncology
FDA approves ibrutinib for previously treated MCL
MDedge Hematology and Oncology